Resumen

CHAPARRO MERIDA, Nataniel Aldo; MORENO SAMPER, Dayany  y  LACATO, Alex Omar Franco. COVID-19 vaccine safety. Rev. perú. med. exp. salud publica [online]. 2021, vol.38, n.4, pp.634-642.  Epub 22-Dic-2021. ISSN 1726-4634.  http://dx.doi.org/10.17843/rpmesp.2021.384.9308.

The development and production of safe and effective vaccines against coronavirus disease 2019 (COVID-19) provides hope for controlling the current pandemic. Adverse events following immunization are unwanted responses or unintended events that must be carefully monitored, as all vaccines, including those developed against SARS-CoV-2, are required to meet safety criteria for administration in humans. Information was collected from the PubMed/Medline database during the months of August 2020 to November 2021. Most adverse events reported in clinical trials were mild or moderate; however, thrombotic events associated with some viral vector-based vaccines against COVID-19 were identified in follow-up studies, although completion of the various ongoing studies and post-marketing surveillance is required to determine all potential adverse events, as well as those of special interest.

Palabras clave : Vaccine; Coronavirus; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Immunogenicity; Efficacy; Adverse events; Clinical Trial; Phase III; Pandemics.

        · resumen en Español     · texto en Español     · Español ( pdf )